Evaluation of the clinical use of tepoxalin and meloxicam in cats.

Article Details

Citation
Copy to clipboard

Charlton AN, Benito J, Simpson W, Freire M, Lascelles BD

Evaluation of the clinical use of tepoxalin and meloxicam in cats.

J Feline Med Surg. 2013 Aug;15(8):678-90. doi: 10.1177/1098612X12473994. Epub 2013 Jan 24.

PubMed ID
23349526 [ View in PubMed
]
Abstract

Medical records where tepoxalin (Zubrin) or meloxicam (Metacam) were prescribed in cats were reviewed and data extracted. Comparisons were performed for exploring changes between pre- and post-non-steroidal anti-inflammatory drug course laboratory tests. Seventy-nine medical records fit the inclusion criteria (n = 57 and n = 22, tepoxalin and meloxicam, respectively). The median dosages administered were 13 and 0.029 mg/kg(/)day (tepoxalin and meloxicam, respectively). Median prescription durations were 11 (2-919) and 93 (4-1814) days for tepoxalin and meloxicam, respectively. Suspected adverse events were reported for tepoxalin (9%, 5/57 cats) and meloxicam (18%, 4/22 cats) a median of 774 and 448 days, respectively, after the prescription started. For cats prescribed meloxicam, there were several statistically significant changes for serum biochemistry and hematology parameters, but median values were within normal limits. These valuable clinical data suggest that tepoxalin and meloxicam are well tolerated in the clinical setting at the doses prescribed in this study.

DrugBank Data that Cites this Article

Drugs